Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at Chardan Capital
Chardan Capital reissued their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $24 ...
What is Leerink Partnrs’ Forecast for AXSM FY2028 Earnings?
Leerink Partnrs lowered their FY2028 earnings per share estimates for Axsome Therapeutics in a research note issued on ...